The Board

Professor Richard Barker – Chairman

Richard BarkerRichard is an internationally respected leader in healthcare and life sciences.

He is Director of the Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), a major UK initiative aimed at transforming the R&D and regulatory processes in life sciences to bring advances more rapidly and affordably to patients.

He was recently appointed as chair of the Precision Medicine Catapult, forging a national strategy in this rapidly developing field.

Richard is also chairman of the South London Academic Health Science Network, accelerating innovation in this region of the NHS, and of the corresponding Genomic Medicine Centre. He also chairs Image Analysis, a UK company using MRI to quantify the impact of therapy on disease. He is a board member of Celgene, a major US-based bio-therapeutics company and of iCo Therapeutics, a Canadian bioscience company.

His 25-year business career in healthcare has spanned biopharmaceuticals, diagnostics and medical informatics – both in the USA and Europe. Most recently, Richard was Director General of the Association of the British Pharmaceutical Industry, Board member of EFPIA (the European industry association) and Council member of IFPMA (the international equivalent).

As a co-founder of Life Sciences UK, member of the NHS Stakeholder Forum, vice-chair of the UK Clinical Trials Collaboration and in many other roles, Richard has advised successive UK governments on healthcare issues, especially those relating to developing, valuing and using new healthcare technologies.

His past leadership roles include head of McKinsey’s European healthcare practice, General Manager of Healthcare Solutions for IBM, and Chief Executive of Chiron Diagnostics. He was also Chairman and Chief Executive of Molecular Staging, a US bioscience company, now part of Qiagen. He therefore has experience in leading and advising a wide range of high-technology companies.

His book on the future of healthcare ‘2030 – The Future of Medicine: Avoiding a Medical Meltdown’ is published by Oxford University Press. He speaks frequently on the future of life sciences and the restructuring of healthcare systems that new technology can enable.

Professor Sir John Bell GBE – Non-Executive Director

Sir John Bell GBEProfessor Sir John Bell GBE, FRS is Regius Professor of Medicine at Oxford University, and Chairman of the UK’s Office for Strategic Coordination of Health Research. Among his achievements, he was responsible for the working party that produced the Academy of Medical Sciences “Strengthening Clinical Research” report highlighting the need for the UK to focus attention on developing expertise in translational research. In 1993, he founded the Wellcome Trust Centre for Human Genetics, and works extensively across the public and private sector, with roles at Roche Holdings AG, the Gates Foundation and Genomics England Limited.  He was appointed Knight Grand Cross of the Order of the British Empire in the 2015 New Year Honours for services to medicine, medical research and the life science industry.

Professor Sir Leszek Borysiewicz FRS – Non-Executive Director

Sir Leszek Borysiewicz FRSProfessor Sir Leszek Borysiewicz FRS is the 345th Vice-Chancellor of the University of Cambridge, a post he has held since 2010. Prior to that, Sir Leszek was CEO of the UK Medical Research Council. From 2001-2007 he was Principal of the Faculty of Medicine and Deputy Rector of Imperial College London, where he led the development of interdisciplinary research between engineering, physical sciences and biomedicine. Early roles were at the Universities of Wales and Cambridge. Sir Leszek was knighted in 2001 for services to medical research and education, is a founding Fellow of the Academy of Medical Sciences and a Fellow of the Royal Society.

Dr Menelas Pangalos – Non-Executive Director

Dr Menelas PangalosDr Menelas (Mene) Pangalos FMedSci is Executive Vice President of AstraZeneca’s Innovative Medicines and Early Development Biotech Unit where he oversees the company’s small molecule discovery research and early development activities. Since joining AstraZeneca in 2010, Mene has led transformation of the company’s commitment to science and is overseeing the creation of AstraZeneca’s new research centre in Cambridge. He completed his BSc in Biochemistry at Imperial College of Science and Technology, and has a PhD in Neurochemistry (Institute of Neurology, London). Mene is a Visiting Professor of Neuroscience at King’s College London, and sits on several academic and public sector bodies including the MRC Council. He is a Fellow of the Academy of Medical Sciences and the Royal Society for Biology.

Dame Julie Moore – Non-Executive Director

Dame Julie Moore

Dame Julie Moore is Chief Executive of University Hospitals Birmingham (UHB) NHS Foundation Trust, and since October 2015, Interim Chief Executive of Heart of England NHS Foundation Trust. She is a graduate nurse, working in clinical practice before moving into management where she has undertaken a range of clinical and director roles. In recognition of the high quality of clinical care at UHB, Julie has been involved in the turnaround of several under-performing hospital Trusts. She has governance and advisory roles at three local academic institutions, and was previously a member of the UK’s Office for Strategic Coordination of Health Research. Julie was made a Dame Commander of the British Empire in the New Year’s Honours in 2012.

Cookies on Catapult explained

To comply with EU directives we now provide detailed information about the cookies we use. To find out more about cookies on this site, what they do and how to remove them, see our information about cookies. Click OK to continue using this site.

OK